Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy

In the era of precision medicine, the impact of personalized dosing of busulfan is not clear. We undertook a retrospective analysis of 78 patients with myeloid malignancies who received fludarabine and busulfan (FluBu4) with or without measuring Bu pharmacokinetics (Bu PK) and those who received bus...

Descripción completa

Detalles Bibliográficos
Autores principales: Farhan, Shatha, Bazydlo, Michael, Neme, Klodiana, Mikulandric, Nancy, Peres, Edward, Janakiraman, Nalini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698787/
https://www.ncbi.nlm.nih.gov/pubmed/29250116
http://dx.doi.org/10.1155/2017/8690416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698787/
https://www.ncbi.nlm.nih.gov/pubmed/29250116
http://dx.doi.org/10.1155/2017/8690416

Ejemplares similares